Your browser doesn't support javascript.
loading
Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy.
Guil-Luna, Silvia; Rivas-Crespo, Aurora; Navarrete-Sirvent, Carmen; Mantrana, Ana; Pera, Alejandra; Mena-Osuna, Rafael; Toledano-Fonseca, Marta; García-Ortíz, María Victoria; Villar, Carlos; Sánchez-Montero, Maria Teresa; Krueger, Janna; Medina-Fernández, Francisco Javier; De La Haba-Rodríguez, Juan; Gómez-España, Auxiliadora; Aranda, Enrique; Rudd, Christopher E; Rodríguez-Ariza, Antonio.
Affiliation
  • Guil-Luna S; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain; Department of Comparative Pathology, Faculty of Veterinary Medicine, Univers
  • Rivas-Crespo A; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain. Electronic address: z02ricra@uco.es.
  • Navarrete-Sirvent C; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain. Electronic address: Carmen.navarretesirvent@imibic.org.
  • Mantrana A; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain. Electronic address: b42masoa@uco.es.
  • Pera A; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Spain. Electronic address: Alejandra.pera@imibic.org.
  • Mena-Osuna R; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain. Electronic address: b72meosr@uco.es.
  • Toledano-Fonseca M; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain. Electronic address: martatoledanofonseca@gmail.com.
  • García-Ortíz MV; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain. Electronic address: mvictoria.garcia@imibic.org.
  • Villar C; Pathological Anatomy Department, Reina Sofía University Hospital, Córdoba, Spain. Electronic address: carlosm.villar.sspa@juntadeandalucia.es.
  • Sánchez-Montero MT; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain. Electronic address: maria.sanchez@imibic.org.
  • Krueger J; Division of Immunology-Oncology Research Center, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada. Electronic address: janna.krueger@web.de.
  • Medina-Fernández FJ; General and Digestive Surgery Department, Reina Sofía University Hospital, Córdoba, Spain. Electronic address: mefef.dr@gmail.com.
  • De La Haba-Rodríguez J; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain; Department of Medicine, Faculty of Medicine, University of Córdoba, Córdoba,
  • Gómez-España A; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain; Department of Medicine, Faculty of Medicine, University of Córdoba, Córdoba, Spain; Medical Oncology Department, Reina Sofía University Hospital,
  • Aranda E; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain; Department of Medicine, Faculty of Medicine, University of Córdoba, Córdoba,
  • Rudd CE; General and Digestive Surgery Department, Reina Sofía University Hospital, Córdoba, Spain; Faculty of Medicine, Universite de Montreal, Montreal, Canada. Electronic address: christopher.e.rudd@umontreal.ca.
  • Rodríguez-Ariza A; Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain; Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain; Andalusia-ROCHE Network Mixed Alliance in Precision Medical Oncology, Spain; Medical Oncology Department, Reina Sofía University Hospital, Córdoba, Spain
Biomed Pharmacother ; 167: 115592, 2023 Nov.
Article in En | MEDLINE | ID: mdl-37778272
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / CD8-Positive T-Lymphocytes Type of study: Prognostic_studies Limits: Humans Language: En Journal: Biomed Pharmacother Year: 2023 Document type: Article Country of publication: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / CD8-Positive T-Lymphocytes Type of study: Prognostic_studies Limits: Humans Language: En Journal: Biomed Pharmacother Year: 2023 Document type: Article Country of publication: France